Shares in Covid-19 vaccine drug developers take different paths as investors bet on race

Photo issued by the University of Oxford of a vial of coronavirus vaccine developed by AstraZeneca and Oxford University. 

The shares in the pharma groups that so far are leading the race to develop Covid-19 vaccines have taken different paths since announcing their results of Phase 3 trials in the last three weeks, as investors bet on the shots most likely to secure regulatory approval by year-end.     

The shares in Britain's AstraZeneca, which is developing a vaccine with Oxford University, have failed to spark despite announcing its results earlier this week to great acclaim in parts of the media.